155 related articles for article (PubMed ID: 28789453)
1. Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.
Miura Y; Kaira K; Sakurai R; Imai H; Tomizawa Y; Sunaga N; Minato K; Hisada T; Oyama T; Yamada M
Oncol Lett; 2017 Aug; 14(2):2369-2378. PubMed ID: 28789453
[TBL] [Abstract][Full Text] [Related]
2. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
3. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
[TBL] [Abstract][Full Text] [Related]
4. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Koh Y; Kim TM; Jeon YK; Kwon TK; Hah JH; Lee SH; Kim DW; Wu HG; Rhee CS; Sung MW; Kim CW; Kim KH; Heo DS
Ann Oncol; 2009 Aug; 20(8):1414-9. PubMed ID: 19468031
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung.
Ohtaki Y; Kaira K; Yajima T; Erkhem-Ochir B; Kawashima O; Kamiyoshihara M; Igai H; Onozato R; Ibe T; Kosaka T; Nakazawa S; Nagashima T; Oyama T; Shirabe K
Thorac Cancer; 2021 Oct; 12(20):2666-2679. PubMed ID: 34453496
[TBL] [Abstract][Full Text] [Related]
6. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.
Sakurai R; Kaira K; Miura Y; Sunaga N; Saito R; Oyama T; Hisada T; Yamada M
Thorac Cancer; 2020 Feb; 11(2):426-435. PubMed ID: 31901017
[TBL] [Abstract][Full Text] [Related]
8. Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma.
Okuda K; Oda R; Suzuki A; Tatematsu T; Haneda H; Moriyama S; Yano M; Nakanishi R
Oncol Lett; 2017 May; 13(5):3144-3150. PubMed ID: 28521419
[TBL] [Abstract][Full Text] [Related]
9. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma.
Imai H; Shimizu K; Kawashima O; Endoh H; Imaizumi K; Goto Y; Kamiyoshihara M; Sugano M; Yamamoto R; Tanaka S; Fujita A; Kogure Y; Seki Y; Mogi A; Oyama T; Minato K; Asao T; Kaira K
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653009
[TBL] [Abstract][Full Text] [Related]
11. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
Miura Y; Kaira K; Sakurai R; Sunaga N; Saito R; Hisada T; Yamada M
Lung Cancer; 2018 Jan; 115():42-48. PubMed ID: 29290260
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
13. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
[TBL] [Abstract][Full Text] [Related]
14. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
16. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
17. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
18. The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.
Sahin TK; Isik A; Guven DC; Ceylan F; Babaoglu B; Akyol A; Yalcin S; Dizdar O
Pancreatology; 2024 Mar; 24(2):279-288. PubMed ID: 38272717
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of class III β-tubulin is associated with unfavourable prognosis in patients with malignant melanoma.
Shimizu A; Kaira K; Yasuda M; Asao T; Ishikawa O
Melanoma Res; 2016 Feb; 26(1):29-34. PubMed ID: 26426765
[TBL] [Abstract][Full Text] [Related]
20. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
